Review of 30 years of ibogaine research finds evidence too weak to support clinical use

The question

What does three decades of human research actually show about whether ibogaine works for addiction and psychiatric conditions, and how safe it is?

What they did

The authors carried out a narrative review of clinical studies on ibogaine published between 1990 and February 2025. They searched databases for randomized controlled trials, open-label studies, retrospective chart reviews and observational research reporting on effectiveness and safety. In total, 24 studies and 38 case reports or case series were included.

What they found

Most of the positive results came from uncontrolled, open-label or retrospective studies, many run outside formal clinical settings and judged to carry a high risk of bias. No double-blind randomized controlled trial has shown that ibogaine or its metabolite noribogaine effectively treats opioid use disorder. Only one small randomized trial reported significant effects, and that was for cocaine use disorder. Observational data hinted at benefit for opioid use disorder, PTSD and polysubstance dependence, but the authors call these findings exploratory. Serious adverse events were reported, particularly heart toxicity linked to QT prolongation, a disturbance of the heart’s electrical rhythm that can be dangerous.

The fine print

This was a narrative review rather than a formal systematic review with pooled statistics, so study selection and weighting involve judgment. The underlying studies were mostly small, uncontrolled and at high risk of bias, and many took place in non-clinical settings. The abstract does not report the total number of people studied or how long participants were followed. This summary is based on the abstract only.

What it means

After thirty years of human reports, the evidence that ibogaine treats addiction or psychiatric conditions remains weak and largely uncontrolled, while documented heart-rhythm risks are serious.

Evidence grade: Low. A narrative (non-systematic) review summarizing mostly uncontrolled, open-label and retrospective studies plus case reports, with a high risk of bias in the underlying evidence.

This summary is based on the study’s published abstract.